所有版权归中国经济网所有。
中国经济网新媒体矩阵
网络广播视听节目许可证（0107190）（京ICP040090）
On January 4, four departments including the National Health Commission jointly published the “Fourth Catalog of Promoted Generic Drugs”, which includes 21 drugs with 47 standards covering treatment fields such as anti-tumor, nervous system, assisted reproductive technology and radiological diagnosis. This system aims to further meet the clinical treatment needs of patients, alleviate the supply shortage of some drugs, and promote the development of high-quality generic drugs in our country. According to reports, since 2019, the National Health Commission, in coordination with multiple departments, has published a catalog of recommended generic drugs in three parts to guide lCompanies to accelerate research and development of generic medicines that are urgently needed for clinical use, whose patents are about to expire or whose supply is in short supply in the market.第四批目录延续“以患者为中心、以临床为重点”的原则，重点关注尚未申请注册、临床稀缺或竞争不足的国家品种。经过多学科专家评审和多轮投票评选，确保入围药品既具有临床价值，又具有研发可行性。该目录包括贝沙罗汀、地夫可特、伊萨君、鲁米匹隆、苏沃来生和地法西林等代表性药物。从效果上看，优先纳入首选指南推荐的国外产品。比如治疗失眠的suvorexan，主要解决入睡困难和长时间保持睡眠的问题，同时也减少了白天嗜睡、疲劳等副作用。 It can cover the shortage of medic拓展我国市场，提供更多临床选择。在不孕不育治疗支持方面，首选副作用较少的重复产品。例如，辅助生殖技术中使用的阴道缓释黄体酮凝胶和栓剂，可以减少辅助生殖技术中体外受精和胚胎移植技术支持过程中长期注射大剂量油溶性注射剂引起的注射部位红、肿、硬结、疼痛、脂膜炎等副作用。确保仿制药推广目录顺利实施 此外，国家卫生健康委会同有关部门建立沟通协商机制，按照职责推动仿制药研发、注册、生产、使用、报销等支持政策的协调配合，促进仿制药合理利用。使用，保障药品供应。